Prime Medicine, Inc. PRME 深 沪
等待开盘 12-18 09:30:00 美东时间
3.78
-0.100
-2.58%
华盛通- 最 高4.12
- 今 开3.94
- 成交量 164.74万股
- 最 低 3.76
- 昨 收 3.88
- 总市值 3.57亿
- 52周最高 6.94
- 市盈率 静 --
- 换手率 1.75%
- 52周最低 1.11
- 委 比 2.03%
- 总股本 9433.60万
- 历史最高 21.73
- 量 比 0.68
- 振 幅 9.28%
- 历史最低 1.11
- 每 手 1
- 风险率 1.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Prime Medicine Announced New England Journal Of Medicine Publication Of PM359 Clinical Data For Two Patients For Treatment Of Chronic Granulomatous Disease
Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the publication of Phase 1/2 clinical data with
12-08 06:28
美股大行评级 | CoreWeave、Monday遭美银、小摩等多家大行下调目标价；中金首予Nebius "跑赢大市"评级，目标价143美元
今日重点评级关注：Piper Sandler：维持MeiraGTx Hldgs"超配"评级，目标价从28美元升至30美元；RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从26美元升至32美元
11-12 11:43
美股大行评级 | 花旗上调英伟达目标价从210美元升至220美元；DraftKings、DoubleVerify遭多家大行下调目标价
今日重点评级关注：Guggenheim：维持InflaRx"买入"评级，目标价从10美元升至22美元；巴克莱：维持Tandem糖尿病护理"超配"评级，目标价从51美元升至55美元
11-11 10:49
Chardan Capital Maintains Buy on Prime Medicine, Lowers Price Target to $9
Chardan Capital analyst Geulah Livshits maintains Prime Medicine (NASDAQ:PRME) with a Buy and lowers the price target from $10 to $9.
11-10 20:21
美股牛股 | ChowChow上市首日飙升215%；波多黎各签署40亿美元LNG协议，NFE飙涨近45%
ChowChow上市首日飙升215%；波多黎各签署40亿美元LNG协议，NFE飙涨近45%；加密货币挖矿的公司BITF涨超16%，月内累涨超110%>>
09-17 16:39
Macy's Increases FY2025 Outlook, Joins REV Group, HealthEquity, Alphabet and Wellness And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mixed, with the Dow Jones index falling over 150 points on Wed...
09-03 22:10
Prime Drink Group Granted Extension for Financial Filings
Dominion Water Reserves ( ($TSE:PRME) ) just unveiled an announcement. Prime Dr...
08-30 10:32
美股大行评级 | 潜在涨幅286.44%！RBC Capital上调Edgewise Therapeutics目标价至49美元，维持"跑赢大市"评级
今日重点评级关注：RBC Capital：维持Edgewise Therapeutics"跑赢大市"评级，目标价从48美元升至49美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从6美元升至7美元
08-11 09:43
Prime Medicine Q2 EPS $(0.41) Misses $(0.39) Estimate, Sales $1.115M Beat $750.000K Estimate
Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.39) by 6.22 percent. This is a 10.87 percent increase over losses of $(0.46) per share from
08-07 20:09
Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates
Prime Medicine reported positive clinical data from its Phase 1/2 trial in Chronic Granulomatous Disease (CGD), demonstrating early efficacy and safety of Prime Editing. The company secured $144.2 million from a follow-on offering and up to $24 million from the Cystic Fibrosis Foundation to advance its pipeline. Allan Reine, M.D., was appointed CEO, leading a strategic restructuring to enhance operational efficiency. The company expects its cash ...
08-07 12:00
